Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

Cantor ups Ardelyx to OW; PT to $10 ahead of October PDUFA date

Cantor Fitzgerald upgraded Ardelyx (NASDAQ:ARDX) to “overweight” from “neutral” and doubled its price target to $10 from $5, citing an upcoming PDUFA date of Oct. 17 for flagship drug, Xphozah, and higher sales...

August 25, 2023

Markets

AGF starts Aspira Women’s Health at buy; PT $5.60

Alliance Global Partners initiated coverage of Aspira Women’s Health (NASDAQ:AWH) with a “buy” rating and price target of $5.60. The stock closed at $2.76 on Aug. 21. Aspira Women’s Health’s proprietary...

August 22, 2023

Markets

Cantor cuts Aravive to neutral; PT to 25 cents on pipeline setback

Cantor Fitzgerald downgraded Aravive (NASDAQ:ARAV) to “neutral” from “overweight” and slashed its price target to 25 cents from $18 after the company indicated it might be forced to cease operations. The stock closed at...

August 22, 2023

Markets

Leerink ups Centessa PT to $11 from $6 on pipeline prospects

Leerink Partners raised its price target for Centessa Pharmaceuticals (NASDAQ:CNTA) to $11 from $6, and reiterated an “outperform” rating, citing an improved outlook for its pipeline. The stock closed at $6.62 on Aug...

August 15, 2023

Markets

Leerink starts Turnstone Biologics at MP; PT $13

Leerink Partners initiated coverage of Turnstone Biologics (NASDAQ:TSBX) with a “market perform” rating and $13 price target. The stock closed at $11.73 on Aug. 14. “We see potential in Turnstone’s selected tumor...

August 15, 2023

Markets

Ladenburg cuts Salarius to neutral; removes PT

Ladenburg Thalmann downgraded Salarius Pharmaceuticals (NASDAQ:SLRX) to “neutral” from “buy” and removed its price target after the company disclosed it is exploring strategic alternatives and implement cost-cutting...

August 11, 2023

Markets

Leerink ups Quanterix to OP; PT to $30

Leerink Partners upgraded Quanterix (NASDAQ:QTRX) to “outperform” from “market perform” and raised its price target to $30 from $25, citing strong evidence for its assays redevelopment effort. Analyst Puneet Souda...

August 8, 2023

Markets

Cantor starts Health Catalyst at OW; PT $16

Cantor Fitzgerald launched coverage of Health Catalyst (NASDAQ:HCAT) with an “overweight” rating and price target of $16, representing a 2024 enterprise value/revenue multiple of 2.3 times. The stock closed at $14.03 on...

August 1, 2023

Markets

Cantor starts Belite Bio at OW; PT $43

Cantor Fitzgerald launched coverage of Belite Bio (NASDAQ:BITR) with an “overweight” rating and a 12-month price target of $43. Belite listed its ADSs on NASDAQ in April 2022; they closed at $20.55 on July 27. Belite...

July 28, 2023

Markets

Leerink slashes Mersana PT to $4 after UPLIFT trial fails

Leerink slashed its price target for Mersana Therapeutics (NASDAQ:MRSN) to $4 from $15, but maintained its “outperform” rating after the UPLIFT clinical trial of upifitamab rilsodotin (UpRi) did not meet its primary...

July 27, 2023

Markets

Stifel starts Aeglea Bio at buy; PT 90 cents

Stifel initiated coverage of Aeglea BioTherapeutics (NASDAQ:AGLE) with a “buy” rating and price target of 90 cents. The stock closed at 59 cents on July 24. Aeglea is a biotechnology company that is now focused on the...

July 25, 2023

Markets

Cantor starts LifeMD at OW; PT $7

Cantor Fitzgerald initiated coverage of LifeMD (NASDAQ:LFMD) with an “overweight” rating and price target of $7. The stock closed at $3.53 on July 20. “We see LifeMD as an undervalued, below-the-radar growth story in...

July 21, 2023

Markets

BTIG reinitiates Orthofix Medical at buy; PT $27

BTIG reinitiated its coverage of Orthofix Medical (NASDAQ:OFIX) with a “buy” rating and $27 price target. The stock closed at $20.65 on July 18. BTIG previously covered the legacy Orthofix from 2017-to-2021 and the...

July 19, 2023

Markets

Stifel ups Black Diamond Therapeutics to buy; PT to $10 on Phase 1 data

Stifel upgraded Black Diamond Therapeutics (NASDAQ:BDTX) to “buy” from “hold” and raised its price target to $10 from $2 after the company reported initial dose escalation data demonstrating anti-tumor activity of BDTX...

June 30, 2023

Markets

Raymond James ups Eupraxia PT on new osteoarthritis data

Raymond James raised its price target for Eupraxia Pharmaceuticals (TSX:EPRX) to $17 (Canadian) from $11, maintaining a “strong buy” rating, after the company reported positive Phase 2b data with EP-104IAR for pain...

June 27, 2023

Markets

Cantor starts AVITA Medical at OW; PT $23

Cantor Fitzgerald launched coverage of AVITA Medical (NASDAQ:RCEL) with an “overweight” rating and $23 target price. The stock closed at $15.71 on June 26. Avita is a regenerative medicine company commercializing its...

June 27, 2023

Markets

RC ups PT; RJ reiterates ‘strong buy’, for Eupraxia on Phase 2b osteoarthritis data

Research Capital raised its price target for Eupraxia Pharmaceuticals (TSX:EPRX) to $25 (Canadian) from $10.30 and maintained a “speculative buy” rating after the company reported positive results from its Phase 2b...

June 26, 2023

Markets

restor3d to acquire Conformis for $2.27 a share

Closely-held restor3d, a leading personalized 3D-printed orthopedic company, will acquire all outstanding shares of Conformis (NASDAQ:CFMS) for $2.27 a share, which represents an approximate 96% premium to the closing...

June 23, 2023

Markets

Raymond James starts Fusion Pharma at OP; PT $13

Raymond James initiated coverage of Fusion Pharmaceuticals (NASDAQ:FUSN) with an “outperform” rating and $13 price target. The stock closed at $4.37 on June 22. Fusion is a precision oncology company that has built a...

June 23, 2023

Markets

Quipt Home Medical up-lists to TSX

Quipt Home Medical (NASDAQ:QIPT; TSXV:QIPT) received final approval to list its common shares on the Toronto Stock Exchange and will commence trading on the TSX at the market open on June 21 under the symbol, QIPT. With...

June 20, 2023

Markets

BTIG starts Beyond Air at buy; PT $15

BTIG initiated coverage of Beyond Air (NASDAQ:XAIR) with a “buy” rating and $15 price target. The stock closed at $5.73 on June 14. Beyond Air is a medical device company that has developed a technology to turn room air...

June 15, 2023

Markets

AGP starts UpHealth at buy; PT $4.30

Alliance Global Partners initiated coverage of UpHealth (NYSE:UPH) with a “buy” rating and price target of $4.30. The stock closed at $1.45 on June 8. UpHealth operates as a digital health services company in the...

June 9, 2023

Cantor ups Ardelyx to OW; PT to $10 ahead of October PDUFA date

AGF starts Aspira Women’s Health at buy; PT $5.60

Cantor cuts Aravive to neutral; PT to 25 cents on pipeline setback

Leerink ups Centessa PT to $11 from $6 on pipeline prospects

Leerink starts Turnstone Biologics at MP; PT $13

Ladenburg cuts Salarius to neutral; removes PT

Leerink ups Quanterix to OP; PT to $30

Cantor starts Health Catalyst at OW; PT $16

Cantor starts Belite Bio at OW; PT $43

Leerink slashes Mersana PT to $4 after UPLIFT trial fails

Stifel starts Aeglea Bio at buy; PT 90 cents

Cantor starts LifeMD at OW; PT $7

BTIG reinitiates Orthofix Medical at buy; PT $27

Stifel ups Black Diamond Therapeutics to buy; PT to $10 on Phase 1 data

Raymond James ups Eupraxia PT on new osteoarthritis data

Cantor starts AVITA Medical at OW; PT $23

RC ups PT; RJ reiterates ‘strong buy’, for Eupraxia on Phase 2b osteoarthritis data

restor3d to acquire Conformis for $2.27 a share

Raymond James starts Fusion Pharma at OP; PT $13

Quipt Home Medical up-lists to TSX

BTIG starts Beyond Air at buy; PT $15

AGP starts UpHealth at buy; PT $4.30

General

More